Literature DB >> 16923437

Risk of death or acute myocardial infarction 10 years after coronary artery bypass surgery in relation to type of diabetes.

Thomas Alserius1, Niklas Hammar, Tobias Nordqvist, Torbjörn Ivert.   

Abstract

BACKGROUND: The aim of this study was to assess the long-term risk of death or acute myocardial infarction (AMI) in patients with diabetes mellitus (DM) compared with that in patients without DM after coronary artery bypass grafting (CABG).
METHODS: National registers were used to record death or AMI occurring in 6727 patients who had CABG during 1980 to 1995. Diabetes mellitus in 856 patients (13%) was classified as type 1 (6%) or type 2 treated with insulin (29%), oral drugs (46%), or diet (19%).
RESULTS: The risk of death < or = 30 days of the operation was increased in patients with insulin-treated type 2 DM (odds ratio [OR] 4.6, 95% CI 2.5-8.4) and in those on oral antidiabetic drugs (OR 2.0, 95% CI 1.0-3.8), but not in diet-treated diabetic patients, compared with that in patients without diabetes. At 10 years, the relative risk of death or having an AMI was 1.8 (95% CI 1.5-2.2) in insulin-treated patients and 1.4 (95% CI 1.2-1.7) in patients on oral drugs. No increased risk of late death or AMI was observed in diet-treated patients with diabetes compared with patients without diabetes. Survival at 10 years without an AMI was 40% in insulin-treated type 2 diabetic patients, 48% if on oral drugs, and 59% if diet managed, compared with 66% in nondiabetic patients.
CONCLUSION: Type 2 DM requiring insulin treatment or oral antidiabetic drugs is associated with an increased early and long-term risk of death or AMI after CABG, whereas diet-treated patients have a risk similar to that in patients without diabetes.

Entities:  

Mesh:

Year:  2006        PMID: 16923437     DOI: 10.1016/j.ahj.2006.02.010

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  12 in total

Review 1.  Effect of hyperglycaemia and diabetes on acute myocardial ischaemia-reperfusion injury and cardioprotection by ischaemic conditioning protocols.

Authors:  Claudia Penna; Ioanna Andreadou; Manuela Aragno; Christophe Beauloye; Luc Bertrand; Antigone Lazou; Ines Falcão-Pires; Robert Bell; Coert J Zuurbier; Pasquale Pagliaro; Derek J Hausenloy
Journal:  Br J Pharmacol       Date:  2020-03-09       Impact factor: 8.739

2.  The impact of diabetes on postoperative outcomes following lower-extremity bypass surgery.

Authors:  Jessica B Wallaert; Brian W Nolan; Julie Adams; Andrew C Stanley; Jens Eldrup-Jorgensen; Jack L Cronenwett; Philip P Goodney
Journal:  J Vasc Surg       Date:  2012-07-21       Impact factor: 4.268

Review 3.  Metformin therapy in diabetes: the role of cardioprotection.

Authors:  Saloua El Messaoudi; Gerard A Rongen; Niels P Riksen
Journal:  Curr Atheroscler Rep       Date:  2013-04       Impact factor: 5.113

4.  Metformin mitigates apoptosis in ischemic myocardium.

Authors:  Nassrene Y Elmadhun; Ashraf A Sabe; Antonio D Lassaletta; Louis M Chu; Frank W Sellke
Journal:  J Surg Res       Date:  2014-05-17       Impact factor: 2.192

5.  The diabetic heart: too sweet for its own good?

Authors:  Hannah J Whittington; Girish G Babu; Mihaela M Mocanu; Derek M Yellon; Derek J Hausenloy
Journal:  Cardiol Res Pract       Date:  2012-02-22       Impact factor: 1.866

6.  Associations of metabolic syndrome and diabetes mellitus with 16-year survival after CABG.

Authors:  Ville Hällberg; Ari Palomäki; Jorma Lahtela; Seppo Voutilainen; Matti Tarkka; Matti Kataja
Journal:  Cardiovasc Diabetol       Date:  2014-01-22       Impact factor: 9.951

Review 7.  Comparing the Clinical Outcomes Between Insulin-treated and Non-insulin-treated Patients With Type 2 Diabetes Mellitus After Coronary Artery Bypass Surgery: A Systematic Review and Meta-analysis.

Authors:  Krishna Munnee; Pravesh K Bundhun; Hongzhi Quan; Zhangui Tang
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

8.  N-acetylcysteine and allopurinol confer synergy in attenuating myocardial ischemia injury via restoring HIF-1α/HO-1 signaling in diabetic rats.

Authors:  Xiaowen Mao; Tingting Wang; Yanan Liu; Michael G Irwin; Jing-song Ou; Xiao-long Liao; Xia Gao; Yuan Xu; Kwok F J Ng; Paul M Vanhoutte; Zhengyuan Xia
Journal:  PLoS One       Date:  2013-07-18       Impact factor: 3.240

9.  Aberrant phenotype in human endothelial cells of diabetic origin: implications for saphenous vein graft failure?

Authors:  Anna C Roberts; Jai Gohil; Laura Hudson; Kyle Connolly; Philip Warburton; Rakesh Suman; Peter O'Toole; David J O'Regan; Neil A Turner; Kirsten Riches; Karen E Porter
Journal:  J Diabetes Res       Date:  2015-04-08       Impact factor: 4.011

10.  Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner.

Authors:  Derek J Hausenloy; Hannah J Whittington; Abigail M Wynne; Shah S Begum; Louise Theodorou; Niels Riksen; Mihaela M Mocanu; Derek M Yellon
Journal:  Cardiovasc Diabetol       Date:  2013-10-22       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.